Manchester Financial Inc Tcr2 Therapeutics Inc. Transaction History

Manchester Financial Inc

  • $374 Million
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 21, 2021
SELL
$16.41 - $24.71 $3,282 - $4,942
-200 Closed
0 $0
Q4 2019

Jan 17, 2020
BUY
$12.17 - $17.88 $2,434 - $3,576
200 New
200 $3,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Manchester Financial Inc Portfolio

Follow Manchester Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manchester Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Manchester Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email